Cognitive-behavioral Treatment for Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02257073
• Other study ID #: CBRA20140102
• Secondary ID: BWS11J067
• Status: Enrolling by invitation
• Phase: N/A
• First received: October 2, 2014
• Last updated: March 31, 2017
• Start date: October 2014
• Est. completion date: July 2020

Study information

• Verified date: March 2017
• Source: Chengdu PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effectiveness of Cognitive-behavioral treatment for people with rheumatoid arthritis

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 150
• Est. completion date: July 2020
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• diagnosed by rheumatology consultants with RA

Exclusion Criteria:

• severe psychological difficulties

• currently receiving mental health care

• any medical condition that might prevent them from safely exercising (e.g. history of more severe heart, lung or cerebrovascular disease)

• previously attended an education programme

• had a Modified Health Assessment Questionnaire score >2 (score range 0-3), that is severe functional problems

• history of organic brain syndrome

• presence of a psychotic disorder

• presence of other uncontrolled medical disorders

• presence of a major communication disorder, illiteracy

• presence of less than an 8th grade education (due to inability to complete questionnaires)

• presence of a therapeutic dosage of an antidepressant medication, or presence of another autoimmune disease/disabling condition

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Behavioral:
• Cognitive-behavioral treatment

• Waiting List

Locations

Country	Name	City	State
China	General Hospital of Chengdu Military Area Command PLA	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Chengdu PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes from baseline in disease activity score in 28 joints(DAS28) at 48 weeks		at 0 week, 12 weeks, 24 weeks, 48 weeks